News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Merck shared updates on the company’s oncology pipeline and focused R&D approach
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Subscribe To Our Newsletter & Stay Updated
